Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Dorocubicel - ExCellThera

Next Previous
Drug Profile

Dorocubicel - ExCellThera

Alternative Names: ECT 001; ECT-001-CB; UM 171 cell therapy - ExCellThera; UM171-Expanded Cord Blood Transplantation; Zemcelpro

Latest Information Update: 23 Jun 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator ExCellThera
  • Developer Cordex Biologics; ExCellThera
  • Class Antineoplastics; Haematopoietic stem cells therapies; Immunotherapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Haematological malignancies; Graft-versus-host disease
  • New Molecular Entity No

Highest Development Phases

  • Preregistration Haematological malignancies
  • Phase I/II Multiple myeloma

Most Recent Events

  • 19 Jun 2025 ExCellThera plans to file regulatory application with the regulatory bodies in USA, Canada, United Kingdom and Switzerland
  • 19 Jun 2025 The CHMP of the EMA recommends approval of dorocubicel for Haematological malignancies in European Union
  • 28 Aug 2024 No recent reports of development identified for phase-I development in Sickle-cell-anaemia(In adolescents, In children, Treatment-experienced, In adults) in USA (Parenteral, Infusion)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top